Abstract CT079: Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial

医学 内科学 安慰剂 临床终点 宫颈癌 临床研究阶段 癌症 外科 肿瘤科 代理终结点 化疗 临床试验 病理 替代医学
作者
Qinglei Gao,Jing Wang,Qin Xu,Ying Tang,Jieqing Zhang,Baoping Chang,Bairong Xia,Wei Duan,Danbo Wang,Lijing Zhu,Ruifang An,Guonan Zhang,Ya‐ling Tang,Jian-Li Huang,Xiang Zhang,Hui Qiu,Wenting Ji,Li Li,Jianqing Zhu,Ding Ma
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (8_Supplement): CT079-CT079
标识
DOI:10.1158/1538-7445.am2023-ct079
摘要

Abstract Background: Patients (pts) with advanced cervical cancer who progressed on first-line treatment have no standard therapy and derive limited benefit from currently available treatment. More effective therapeutic strategies are required. This phase II trial was conducted to evaluate the efficacy and safety of IBI310 (anti-CTLA-4 mAb) plus sintilimab (sint) versus sint in pts with recurrent/metastatic cervical cancer. Here we present the efficacy and safety results for pts in sint plus placebo group. Methods: Pts aged 18-75 years, with histologically or cytologically confirmed cervical cancer who had progressed on or been intolerant to first-line or above platinum-based chemotherapy were enrolled. Pts in sint plus placebo group received sint (200mg) plus placebo IV Q3W for 4 cycles followed by sint monotherapy till disease progression, intolerable toxicity, withdrawal of informed consent, death, or for up to 24 months. The primary endpoint was objective response rate (ORR) assessed by IRRC per RECIST V1.1. The data cutoff date was April 20, 2022. Results: Overall, 101 pts were enrolled and received at least one dose of assigned treatment (median age of 53.0 years, 71.3% pts with PD-L1 CPS ≥1, 91.0% pts with squamous-cell carcinoma, and 36.6% pts with ≥2 lines of prior systemic therapy). The median treatment exposure was 18.0 weeks. The IRRC-assessed confirmed objective response rate (ORR) was 24.5% (95%CI: 16.4%-34.2%), disease control rate was 56.1% (95%CI: 45.7%-66.1%), and median duration of response was not reached. Pts with PD-L1 CPS ≥1 showed numerically higher ORR versus those with CPS <1 (32.9% vs 17.2%). With a median follow-up of 8.3 months, median PFS was 2.7 months (95%CI: 1.5-4.3). Median overall survival (OS) was not reached; OS rate was 89.6% (95%CI: 80.9%-94.5%) at 6 months and 65.5% (95%CI: 50.9%-76.7%) at 12 months. Treatment-related adverse events (TRAEs) occurred in 75.2% pts, with the most common being anaemia (13.9%), hypothyroidism (12.9%), white blood cell count decreased (12.9%), and hyperthyroidism (10.9%). 18.8% pts experienced CTCAE Grade 3 or higher TRAEs (no TRAE leading to death occurred). TRAEs leading to drug discontinuation occurred in 1 pt (myocarditis, grade 2). Conclusion: This study demonstrated favorable antitumor activity and acceptable safety with sintilimab alone over available therapies in ≥2 line advanced cervical cancer. ClinicalTrials.gov identifier: NCT04590599 Citation Format: Qinglei Gao, Jing Wang, Qin Xu, Ying Tang, Jieqing Zhang, Baoping Chang, Bairong Xia, Wei Duan, Danbo Wang, Lijing Zhu, Ruifang An, Guonan Zhang, Yaling Tang, Jianli Huang, Xiang Zhang, Hui Qiu, Wenting Ji, Li Li, Jianqing Zhu, Ding Ma. Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT079.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
魈玖完成签到,获得积分10
刚刚
ll完成签到,获得积分10
刚刚
shawn_89完成签到,获得积分10
刚刚
1秒前
wdw2501发布了新的文献求助10
1秒前
哈基咪完成签到,获得积分10
1秒前
风吹麦浪的应助被tianfx3采纳,获得10
1秒前
隐形曼青的应助被笨笨的含莲采纳,获得10
2秒前
张继科keke发布了新的文献求助10
2秒前
动听的秋灵完成签到,获得积分10
2秒前
酸甜完成签到,获得积分10
2秒前
爆米花的应助被Bilibala采纳,获得10
2秒前
3秒前
lixm316完成签到,获得积分10
3秒前
sink发布了新的文献求助10
3秒前
Flyzhang完成签到,获得积分10
3秒前
毛果果发布了新的文献求助10
3秒前
3秒前
3秒前
派先生丶的应助被cc采纳,获得10
3秒前
科研通AI2S的应助被时尚丸子采纳,获得10
3秒前
111完成签到,获得积分10
4秒前
研友_wZr5Rn发布了新的文献求助10
4秒前
无语的怜梦完成签到,获得积分10
4秒前
zad完成签到,获得积分10
4秒前
甜甜的契完成签到,获得积分10
4秒前
l895365038发布了新的文献求助10
5秒前
5秒前
huimin发布了新的文献求助10
5秒前
wangjian完成签到,获得积分10
5秒前
ksduoiwex完成签到,获得积分10
6秒前
就是好命完成签到,获得积分10
6秒前
6秒前
共享精神的应助被小杰采纳,获得10
6秒前
Akim的应助被调皮枫叶采纳,获得10
6秒前
霍双帅完成签到 ,获得积分10
6秒前
6秒前
wanci的应助被tinna采纳,获得10
6秒前
6秒前
曼波发布了新的文献求助30
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159581
求助须知:如何正确求助?哪些是违规求助? 9555100
关于积分的说明 21724719
捐赠科研通 7749543
什么是DOI,文献DOI怎么找? 3427281
关于科研通互助平台的介绍 2552278
邀请新用户注册赠送积分活动 2471619